Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer.

Gasparri, Maria Luisa; Grandi, Giovanni; Bolla, Daniele Maik; Gloor, Beat; Imboden, Sara; Imboden, Sara; Panici, Pierluigi Benedetti; Mueller, Michael; Mueller, Michael; Papadia, Andrea (2015). Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer. Journal of cancer research and clinical oncology, 142(7), pp. 1509-1520. Springer 10.1007/s00432-015-2090-3

[img] Text
Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer..pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (475kB) | Request a copy

PURPOSE Surgical cytoreduction remains a cornerstone in the management of patients with advanced and recurrent epithelial ovarian cancer. Parenchymal liver metastases determine stage VI disease and are commonly considered a major limit in the achievement of an optimal cytoreduction. The purpose of this manuscript was to discuss the rationale of liver resection and the morbidity related to this procedure in advanced and recurrent ovarian cancer. METHODS A search of the National Library of Medicine's MEDLINE/PubMed database until March 2015 was performed using the keywords: "ovarian cancer," "hepatic," "liver," and "metastases." RESULTS In patients with liver metastases, hepatic resection is associated with a similar prognosis as stage IIIC patients. The length of the disease-free interval between primary diagnosis and occurrence of liver metastases, as well as residual disease after resection, is the most important prognostic factors. In addition, the number of liver lesions, resection margins, and the gynecologic oncology group performance status seem to play also an important role in determining outcome. CONCLUSIONS In properly selected patients, liver resections at the time of cytoreduction increase rates of optimal cytoreduction and improve survival in advanced-stage and recurrent ovarian cancer patients.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Gynaecology
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Visceral Surgery
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Endometriose und gynäkologische Onkologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Endometriose und gynäkologische Onkologie

UniBE Contributor:

Bolla, Daniele Maik; Gloor, Beat; Imboden, Sara; Imboden, Sara; Mueller, Michael; Mueller, Michael and Papadia, Andrea

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1432-1335

Publisher:

Springer

Language:

English

Submitter:

Lilian Karin Smith-Wirth

Date Deposited:

02 Mar 2016 15:15

Last Modified:

28 Feb 2017 09:03

Publisher DOI:

10.1007/s00432-015-2090-3

PubMed ID:

26660323

Uncontrolled Keywords:

Cytoreduction; Debulking surgery; Hepatectomy; Liver metastases; Ovarian cancer; Recurrent ovarian cancer

BORIS DOI:

10.7892/boris.77505

URI:

https://boris.unibe.ch/id/eprint/77505

Actions (login required)

Edit item Edit item
Provide Feedback